At 8.0% CAGR, North America Organ Preservation Solution Market is Projected to be worth US$ 2,26,118.82 thousand by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America organ preservation solution market was valued at US$ 1,23,239.05 thousand in 2023 and is expected to reach US$ 2,26,118.82 thousand by 2031, registering a CAGR of 8.0% from 2023 to 2031. Shift toward machine perfusion technique and strategic initiatives by market players are among the critical factors attributed to drive the North America organ preservation solution market growth.

The machine perfusion technique involves continuously providing artificial perfusion to the blood vessels of a grafted organ. This helps actively control the temperature, partial oxygen pressure, chemical composition, and mechanical stress of the internal environment of the organ. Machine perfusion is an advanced technology involving organ perfusion with a controlled perfusion flow. This method helps maintain the organ's microvasculature, provide oxygen and nutrients to support tissue metabolism, and remove toxic metabolic waste. Ex-vivo machine perfusion devices have been studied for their function in various temperature conditions, e.g., normothermic machine perfusion (NMP) at 35–38°C, subnormothermic machine perfusion (SNMP) at 20–34°C, controlled oxygenated rewarming (COR) at 8–20°C, and hypothermic machine perfusion (HMP) at 0–8°C. The success of organ preservation using dynamic machine perfusion, which operates with blood-based perfusates at close-to-physiological temperatures, has encouraged more in-depth studies on organ preservation and repair/reconditioning. Prolonged machine perfusion outside the body allows organ repair and reprogramming, necessitating the further exploration of new strategies to enhance the quality of donor grafts before transplantation. This technology has shown clinical efficacy in kidney, liver, and lung transplantation. In liver transplantation, machine perfusion reduces ischemia-reperfusion injury (I/R injury), protects the endothelium, prevents biliary complications, and assesses graft viability before transplantation. The time of machine perfusion outside the body can be extended by optimizing current perfusates by adding essential components such as amino acids to meet metabolic needs. Therefore, the shift toward the machine perfusion technique is expected to emerge as a new trend in the organ preservation solution market soon.

On the contrary, the expensive organ transplant surgeries hamper the growth of North America organ preservation solution market.

Based on product, the North America organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held 36.5% market share in 2023, amassing US$ 44,993.77 thousand. It is projected to garner US$ 83,273.97 thousand by 2031 to register 8.1% CAGR during 2023–2031.

In terms of application, the North America organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held 45.7% share of North America organ preservation solution market in 2023, amassing US$ 56,339.66 thousand. It is anticipated to garner US$ 1,04,734.74 thousand by 2031 to expand at 8.2% CAGR during 2023–2031.

By type, the North America organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held 59.2% share of North America organ preservation solution market in 2023, amassing US$ 72,957.04 thousand. It is projected to garner US$ 1,35,766.25 thousand by 2031 to expand at 8.2% CAGR from 2023 to 2031.

Based on end user, the North America organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held 57.5% share of North America organ preservation solution market in 2023, amassing US$ 70,883.45 thousand. It is predicted to garner US$ 1,33,294.50 thousand by 2031 to expand at 8.3% CAGR between 2023 and 2031.

Based on country, the North America organ preservation solution market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.3% share of North America organ preservation solution market in 2023. It was assessed at US$ 1,02,627.76 thousand in 2023 and is likely to hit US$ 1,91,357.09 thousand by 2031, registering a CAGR of 8.2% during 2023–2031.

Key players operating in the North America organ preservation solution market are Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, 21ST Century Medicine, and Bridge to Life Ltd., among others.

• In February 2024, Bridge to Life reintroduces EasiSlush to the US market, meeting high demand for easy-to-use sterile slush for organ transplantation. EasiSlush is renowned for its ease of use, high quality, and portability, making it the preferred choice for organ transplant professionals.
• In May 2020, TransMedics a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported positive top-line results from its U.S. Pivotal OCS Liver PROTECT Trial. The trial achieved its primary clinical objectives by meeting both the primary and secondary effectiveness and safety endpoints.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com